Holowesko Partners’s Pfizer PFE Stock Holding History

Holowesko Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-15,500	Closed	-$915K	–	34
2021 Q4	$915K	Sell	15,500 -21,000	-58%	-$1.04M	0.37%	28
2021 Q3	$1.57M	Sell	36,500 -311,000	-89%	-$13.8M	0.58%	23
2021 Q2	$13.6M	Buy	347,500 +4,500	+1%	+$175K	3.45%	11
2021 Q1	$12.4M	Buy	+343,000	New	+$12.2M	3.33%	12
2015 Q4	–	Sell	-940,484	Closed	-$28M	–	36
2015 Q3	$28M	Sell	940,484 -274,040	-23%	-$8.79M	1.95%	24
2015 Q2	$38.6M	Buy	1,214,524 +81,474	+7%	+$2.66M	2.4%	19
2015 Q1	$37.4M	Sell	1,133,050 -923,304	-45%	-$29.4M	2.92%	18
2014 Q4	$60.8M	Buy	2,056,354 +378,386	+23%	+$10.8M	5.32%	6
2014 Q3	$47.1M	Buy	1,677,968 +1,011,840	+152%	+$28.4M	3.69%	11
2014 Q2	$18.8M	Buy	+666,128	New	+$19M	1.13%	29
2013 Q4	–	Sell	-967,639	Closed	-$26.4M	–	41
2013 Q3	$26.4M	Sell	967,639 -47,363	-5%	-$1.29M	2.71%	15
2013 Q2	$27M	Buy	+1,015,002	New	+$28M	2.2%	19

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Holowesko Partners's PFE Position: Q1 2022 in Review

Holowesko Partners sold out of Pfizer (PFE) in Q1 2022, closing a stake of 15,500 shares — an estimated $915K sold.

Holowesko Partners first reported a position in PFE in Q2 2013 and held it in 12 quarters. The position peaked at $60.8M in Q4 2014. 3,196 funds tracked by Wall St. Rank hold PFE as of Q1 2022.

Holowesko Partners reported no remaining Pfizer position as of Q1 2022 after selling out during the quarter.
Holowesko Partners sold 15,500 Pfizer shares in Q1 2022, an estimated $915K.
Holowesko Partners first reported a position in Pfizer in Q2 2013 and held it in 12 quarters.
Holowesko Partners's Pfizer position peaked at $60.8M in Q4 2014.
3,196 funds tracked by Wall St. Rank held Pfizer as of Q1 2022.

Based on Holowesko Partners's 13F filing for Q1 2022, filed 13 May 2022.